BackLakeShore Biopharma Co Overview

LakeShore Biopharma Co Receivables

Latest receivables for YS: $500M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$501.79M
↑ 12.97% YoYΔ $57.63M vs prior year quarter

Peer average

Loading

LakeShore Biopharma Co Receivables History

Loading

LakeShore Biopharma Co vs. peers: Receivables Comparison

Loading

LakeShore Biopharma Co Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

LakeShore Biopharma Co (YS) FAQ

LakeShore Biopharma Co (YS) currently reports a receivables of $500M as of March 2025. That compares with $440M in the prior-year period — up 13.0% year over year. Use the charts on this page to explore LakeShore Biopharma Co's receivables history and peer comparisons.

LakeShore Biopharma Co's receivables increased from $440M to $500M — a 13.0% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

LakeShore Biopharma Co reported $500M in receivables as of March 2025. That compares with $440M in the prior-year period — up 13.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $500M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for LakeShore Biopharma Co, and consider following YS for alerts when major investors trade the stock.